Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
Ontology highlight
ABSTRACT: This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab (a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for eight cycles before surgery and part of patients may exempt from surgery.
DISEASE(S): Dmmr Colorectal Cancer,Colorectal Neoplasms
PROVIDER: 46532 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA